300
Participants
Start Date
December 17, 2021
Primary Completion Date
July 31, 2023
Study Completion Date
July 31, 2023
percutaneous pulmonary valve implantation (PPVI)
The only inclusion criterion is a successful PPVI to treat RVOT dysfunction. Procedural techniques were at each operator's discretion as well as post-procedure treatments and patient's follow-up. As we sought to assess IE incidence during follow-up, patients who underwent catheterization for intended PPVI but who did not had a successful valve implantation were not included. Successful PPVI was defined as patient discharged alive without valve surgery after successful valve implantation in the RVOT.
Clinique Pasteur, Toulouse
CHU Toulouse, Toulouse
CHU Bordeaux, Bordeaux
CHU de Grenoble, Grenoble
CHU de Nantes, Nantes
CHRU Lille, Lille
Hopital Marie Lannelongue, Le Plessis-Robinson
CHU de la Timone, Marseille
Medical Hospital of the university of Munich, Munich
Bambin Gesù Hospital,, Rome
Hospital de Santa Marta, Centro Hospitalar Lisboa Central-EPE, Lisbon
King Faisal Hospital, Jeddah
Vall d'Hebron University Hospital, Barcelona
12 de Octubre University Hospital,, Madrid
H. Ramón y Cajal University Hospital, Madrid
Cardiology university Hospitals Birmingham, Birmingham
Bristol Heart Institute, University Hospitals Bristol & Weston NHS Foundation Trust, Bristol
Royal Brompton Hospital, London
Centre Chirurgical Marie Lannelongue
OTHER